ICMR claims - Covaxin is most effective on Double Mutant Coronavirus

ICMR claims - Covaxin is most effective on Double Mutant Coronavirus

The Indian Council of Medical Research (ICMR) gave good news on Tuesday. ICMR stated that covaxin also protects against double mutant corona variants. Based on its study, the ICMR stated that this vaccine is also effective on the Brazilian version, the UK version, and the South African version and provides protection against them.

These variants are being blamed for the ongoing second wave in the country. The double mutant corona variant encountered in 10 states of India is the deadliest. It not only transmits rapidly but also causes a lot of damage in a very short period. At the same time, UK, Brazil, and South African variants have also emerged in the growing re-infection cases in India.

Covaxin effective up to 78% in third phase clinical trials

Bharat Biotech, a Hyderabad-based company that manufactures the Corona vaccine, and the Indian Council of Medical Research (ICMR) have released an interim clinical trial report for the third phase of covaxine. The report described covaxin manufactured in India as clinically 78% and up to 100% effective on patients severely affected by corona. The company, in its second analysis, researched 87 properties of Corona.

The company subsequently analyzed 127 symptoms for the third phase following the increased infection. In this, covaxin efficacy was found to be up to 78%. The company will release the final vaccine report in June. The third phase study included 25,800 people between the ages of 18–98, with 10% of those over 60 years.

Bharat Biotech has made Covaxin on a traditional platform. In this, the inactivated virus is injected into the body, which does not grow in the body, but it prepares antibodies to fight. The good thing is that it targets the entire virus, so it is effective even on the changes that occur in it. The best thing is that covaxin is the first such vaccine in the world, which has the power to fight all the variants.

Triple variants of coronavirus become trouble for Maharashtra and Delhi

The ICMR has given relief news about covaxin, but now the new variant of Corona has become troublesome. According to scientists, the triple mutant variant of Corona is now spreading in the country. This new variant is made up of three different strains of Corona. Experts believe that people in states like Delhi, West Bengal, and Maharashtra are falling victim to this variant.

Clinical trial results have been much better

The trial of indigenous covaxin has yielded much better results. According to the final results of Phase-3 clinical trials, the vaccine has proved to be effective up to 81%. The government had given emergency approval to the vaccine in the first week of January. This decision of the government was on the target of experts as they were against Emergency Approval without seeing the Phase-3 results.

Hyderabad-based company Bharat Biotech has developed this vaccine in collaboration with the Indian Council of Medical Research (ICMR). The special thing is that many ministers, including Prime Minister Narendra Modi, have taken dosages of Covaxin recently. Dr. Balaram Bhargava, Director General of ICMR said that in less than 8 months, Corona Vaccine-Covaxin has been developed and it gives a true picture of self-reliant India.

Covaxin effective against all variants of Corona

Dr. Krishna Alla, chairman and managing director of Bharat Biotech, says that the vaccine has been used on 27,000 volunteers in all three phases of clinical trials. With the results of Phase-3 clinical trials, it has been proven that covaxin is effective against coronaviruses. This vaccine is also effective against other variants of coronavirus that are rapidly emerging.

Covaxin is the best option in the Indian Vaccine Supply chain

Covaxin or BBV152 is a Whole Viron inactivated SARS-CoV-2 vaccine. It is made from Vero Sales. It is stable at 2 to 8 °C and is being transported in ready-to-use liquid formation. For this reason, this vaccine is suitable for existing vaccine supply chain channels. BBV152 is also accompanied by a 28-day open voice policy, which reduces vaccine waste by 10-30%.

Bharat Biotech is also preparing a nasal vaccine

Bharat Biotech, which is making covaxin in India, started trials of its nasal vaccine Coroflu in January. According to Dr. Krishna Alla, the founder of Bharat Biotech, the nasal vaccine has to be given only once. This has proved to be a better option in the research conducted so far. For this, the company has tied up with Washington University.

According to the Clinical Trials Registry, 175 people have been given this nasal vaccine in four cities. The results of its Phase-1 trials are expected to be out in a few days. The good thing is that it will be given through nasal spray and will block only the entry points of the virus. Scientists believe that the corona enters the body through the nose and worsens the condition, so the nasal spray may prove to be effective.

Alpha Eye Thoughts:

Research has demonstrated that Covaxin vaccines are 78% effective, and these data have also been shown to be true in trials that have been conducted on high-risk and elderly studies. It is a common misconception that this means that only 78% of the people who receive the vaccine will be safe and that the remaining 12% will be more likely to have corona.

78% effectiveness means that people with the vaccine have a 78% lower risk of COVID-19 than the control group. In research, it has been found that complete vaccination will bring the corona outbreak rate to 0.5%. At such low rates, vaccines will allow society to return to 'normal' and restrictions will be permanently reduced. In the view of Alpha Eye, vaccination is very important, and getting the whole population vaccinated should be the priority of the government. We have examples from Israel and the UK that have been able to control the corona only through their effective vaccination programs. Alpha Eye hopes that all people will participate more in vaccination and the country will soon be corona-free.

Post a Comment